A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Phase 1 Unknown 74 enrolled Shanghai Miracogen Inc.

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.

Timeline

Start: 2018-11-21
Primary completion: 2022-10
Completion: 2022-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TRASTUZUMAB VEDOTIN	Unknown	—	Intravenous

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Summary

Timeline

Drugs

Indications